| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42000264 | EBV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
| TVIS30063496 | HIV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
| TVIS30063497 | HIV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
| TVIS30063498 | HIV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
| TVIS30063499 | HIV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
| TVIS30063500 | HIV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
| TVIS20040727 | HPV | ENSG00000169567.13 | protein_coding | HINT1 | No | No | 3094 | P49773 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HINT1 |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0001473 |
| UniProt ID | P49773 |
| Regulation Type | product of |
| PubMed IDs | 17337452; 17158446; 17217311 |
| Citations | Chou TF, Tikh IB, Horta BA, Ghosh B, De Alencastro RB, Wagner CR: Engineered monomeric human histidine triad nucleotide-binding protein 1 hydrolyzes fluorogenic acyl-adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate. J Biol Chem. 2007 May 18;282(20):15137-47. Epub 2007 Mar 2.@@Chou TF, Wagner CR: Lysyl-tRNA synthetase-generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins. J Biol Chem. 2007 Feb 16;282(7):4719-27. Epub 2006 Dec 8.@@Chou TF, Baraniak J, Kaczmarek R, Zhou X, Cheng J, Ghosh B, Wagner CR: Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Mol Pharm. 2007 Mar-Apr;4(2):208-17. Epub 2007 Jan 12. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
